Curated News
By: NewsRamp Editorial Staff
May 28, 2025
Quantum BioPharma Receives Approval for Phase 2 Clinical Trial of FSD202 for Chronic Pain Associated with MCAS
TLDR
- Quantum BioPharma (NASDAQ: QNTM) received HREC approval in Australia for a Phase 2 trial targeting chronic pain.
- FSD202, based on ultra-micronized PEA, aims to reduce pain in patients with MCAS by targeting inflammation-related conditions.
- The trial may offer a new therapeutic option for MCAS, a debilitating disorder, emphasizing the need for safe alternatives.
- Quantum BioPharma's FSD202 trial aims to advance clinical development in treating chronic pain with innovative biotech solutions.
Impact - Why it Matters
This news matters as it highlights a significant step forward in the development of a potential treatment for chronic pain related to MCAS, providing hope for patients with this challenging disorder. The approval of the Phase 2 trial underscores the commitment of Quantum BioPharma to address the unmet medical needs of those suffering from musculoskeletal nociplastic pain.
Summary
Quantum BioPharma (NASDAQ: QNTM) has received HREC approval in Australia to begin a Phase 2 clinical trial for FSD202, a potential treatment for chronic pain associated with MCAS. The trial will enroll 60 patients to measure pain reduction over 56 days, offering hope for those suffering from this debilitating disorder. Executives underscored the urgent need for safe alternatives and expressed readiness to move forward with clinical development.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Quantum BioPharma Receives Approval for Phase 2 Clinical Trial of FSD202 for Chronic Pain Associated with MCAS
